Abstract
KEYNOTE-024 compared single agent pembrolizumab to platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) with PDL1 >50%, illustrating improved progression free survival (PFS) and overall survival (OS) for pembrolizumab. The objective of this study is to identify the proportion of real-world NSCLC patients who have a long-term benefit with first line pembrolizumab and examine their characteristics compared to patients who show limited benefit to the drug.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
